Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Combination therapy in benign prostatic hyperplasia (BPH)].

F Desgrandchamps1

  • 1Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France. francois.desgrandchamps@sls.ap-hop-paris.fr

Annales D'Urologie
|January 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection.

The French journal of urology·2023
Same author

[Profile and immune environment of upper tract urothelial carcinoma].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

Salvage Percutaneous Cryoablation for Bleeding Upper Tract Urothelial Carcinoma.

Cardiovascular and interventional radiology·2022
Same author

Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same author

Morbidity and long-term results of subcutaneous pyelovesical bypass in chronic ureteral obstruction.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021
Same author

[Active surveillance of prostate cancer: treatement-free survival according to restricted or expanded eligibility criteria].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020
Same journal

Prostate cancer at the 2007 ASCO meeting: an urologist's perspective.

Annales d'urologie·2008
Same journal

[Surgical treatment of ureteropyelic junction stenosis using robotic-assisted laparoscopy].

Annales d'urologie·2008
Same journal

[Robotic-assisted laparoscopy: general principles].

Annales d'urologie·2008
Same journal

[De novo tumours of renal transplants].

Annales d'urologie·2008
Same journal

[Immunosuppression in kidney transplantation].

Annales d'urologie·2008
Same journal

[Surgical complications in kidney transplantation].

Annales d'urologie·2008
See all related articles

Combination therapy for benign prostatic hyperplasia (BPH) offers rational treatment options. Combining medications like alpha-blockers and 5-alpha-reductase inhibitors can effectively manage BPH symptoms and gland size.

Area of Science:

  • Urology
  • Pharmacology

Context:

  • Benign prostatic hyperplasia (BPH) is a complex chronic disorder.
  • Current BPH management often involves empirical combination therapy.
  • Advances in understanding BPH pathophysiology enable more rational therapeutic approaches.

Purpose:

  • To explore the theoretical benefits of combination therapy for BPH.
  • To review the mechanisms of action for different BPH drug classes.
  • To identify evidence-based indications for specific BPH combination therapies.

Summary:

  • Alpha-blockers relax prostatic smooth muscle, while 5-alpha-reductase inhibitors reduce prostate volume.
  • Antimuscarinics can treat irritative bladder symptoms associated with BPH.
  • Combination therapy with an alpha-blocker and 5-alpha-reductase inhibitor is suggested for BPH patients with prostates >40g and PSA >1.6 ng/ml.

Related Experiment Videos

  • Combining antimuscarinics with other agents may benefit patients with significant irritative BPH symptoms.
  • Alpha-blockers and phosphodiesterase type 5 inhibitors may help patients with lower urinary tract symptoms (LUTS) and erectile dysfunction.

    • Impact:

    • Provides a framework for rational, evidence-based BPH combination therapy.
    • Highlights specific patient subgroups who may benefit from particular drug combinations.
    • Supports the move away from empirical BPH treatment towards targeted therapeutic strategies.